20 pp.
20 pp.
| 1182 K 20 pp. | |
| View Document | ||
| Title | Production of Medical Radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for Cancer Treatment and Arterial Restenosis Therapy after PTCA | |
| Author(s) | Knapp, F. F. Jr.; Beets, A. L.; Mirzadeh, S.; Alexander, C. W.; Hobbs, R. L. | |
| Publication Date | June 1998 | |
| Report Number | ORNL/CP--97929 | |
| Unique Identifier | ACC0024 | |
| Other Numbers | CONF-980446--; Legacy ID: DE98003519; OSTI ID: 661540 | |
| Research Org | Oak Ridge National Laboratory, TN (United States) [ORNL] | |
| Contract No | AC05-96OR22464 | |
| Sponsoring Org | USDOE Assistant Secretary for Human Resources and Administration, Washington, DC (DOE/HR) | |
| Other Information | 13th Radiochemical Conference, Marianske Lazne (Czech Republic), 19-24 Apr 1998; | |
| Subject | 22 Nuclear Reactor Technology; 55 Biology and Medicine, Basic Studies; Research, Test, Training, Production, Irradiation, Materials Testing Reactors; Unsealed Radionuclides in Therapy | |
| Keywords | Radiopharmaceuticals; Isotope Production; HFIR Reactor; Experimental Data; Radiotherapy; Neoplasms; Skeletal Diseases; Vascular Diseases | |
| Related Web Pages | Peaceful Uses of the Atom | |
| Abstract | The High Flux Isotope Reactor (HFIR) at the Oak Ridge National Laboratory (ORNL) represents an important resource for the production of a wide variety of medical radioisotopes. In addition to serving as a key production site for californium-252 and other transuranic elements, important examples of therapeutic radioisotopes which are currently routinely produced in the HFIR for distribution include dysprosium-166 (parent of holmium-166), rhenium-186, tin-117m and tungsten-188 (parent of rhenium-188). The nine hydraulic tube (HT) positions in the central high flux region permit the insertion and removal of targets at any time during the operating cycle and have traditionally represented a major site for production of medical radioisotopes. To increase the irradiation capabilities of the HFIR, special target holders have recently been designed and fabricated which will be installed in the six Peripheral Target Positions (PTP), which are also located in the high flux region. These positions are only accessible during reactor refueling and will be used for long-term irradiations, such as required for the production of tin-117m and tungsten-188. Each of the PTP tubes will be capable of housing a maximum of eight HT targets, thus increasing the total maximum number of HT targets from the current nine, to a total of 57. In this paper the therapeutic use of reactor-produced radioisotopes for bone pain palliation and vascular brachytherapy and the therapeutic medical radioisotope production capabilities of the ORNL HFIR are briefly discussed. | |
| 1182 K 20 pp. | |
| View Document | ||
